A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients

NCT05552339 | Completed

• 1 other identifier: 22280
• Study Type: observational
• Target: 348
• Locations: 1 country
• Sites: 1

Brief Summary

This is an observational study in which data from people with type 2 diabetes mellitus (T2DM) in Germany who use the medical app "myTherapy" are studied. In observational studies, only observations are made without specified advice or interventions. In people with T2DM, the body does not make enough of a hormone called insulin or does not use insulin well enough. The resulting high blood sugar level can cause damage to the kidneys over time. As a result, chronic kidney disease (CKD) can occur as a complication of T2DM. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive decrease in the kidneys' ability to properly filter the blood. Abnormal amounts of proteins such as albumin in the urine are a sign of kidney damage, as proteins are normally kept in the blood. The amount of albumin in the urine is measured as so-called urine-albumin-creatinine-ratio (UACR) in this study. Studies in people with T2DM and CKD in a real-world care setting are limited, particularly those that look at the number of people concerned over time. The main purpose of this study is to learn how many people with T2DM have also increased amounts of albumin in the urine (UACR level) in users of the medical app "myTherapy" in Germany. In addition, researchers want to learn how these albumin levels change over time. To answer this, the researchers will collect the participant's UACR level at start of the study and about 12 months later. The UACR is measured by the participant's physician during routine care using urine dip-sticks. All participants of this study are already receiving or will receive one of the available T2DM treatments prescribed by their doctors according to the approved use or are regularly using devices to check their blood sugar levels. And they use the "myTherapy" app to support and track their T2DM therapy. The data collected includes both participant-reported data and physician-provided lab values. All data are entered into the "myTherapy" app by the participant. They will be collected from October 2022 to December 2024 and cover a period of up to 15 months per participant. Besides this data collection, no further tests or examinations are planned in this study.

Conditions

Chronic Kidney Disease; Type 2 Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Number of patients with Urine albumin-creatinine ratio (UACR) values between 30 and 299 mg/g and above 300 mg/g

  The urine albumin-creatinine ratio (UACR) measured by a healthcare professional and provided to the patient

  Up to 15 months after the date the initial UACR test took place

Secondary Outcomes (8)

• Number of patients changing their UACR values regarding their baseline Albumin-Creatinine-Ratio (ACR) classification.

  Up to 15 months after the date the initial UACR test took place

• Number of patients with hypertension and nephrotoxic co-medication

  12 month previous informed consent date until end of observation

• Mean EuroQol-5 Dimensions (EQ-5D)

  Up to 15 months after the date the initial UACR test took place

• Diabetes Treatment Satisfaction Questionnaire (DTSQ)

  Up to 15 months after the date the initial UACR test took place

• Number of patients with CKD, Hypertension, Type 2 Diabetes Mellitus and tobacco use

  Up to 15 months after the date the initial UACR test took place

Study Arms (1)

Type 2 Diabetes Mellitus patients

MyTherapy App users with Self-reported Type 2 Diabetes Mellitus who had been prescribed drugs for their T2DM.

Drug: Finerenone (Kerendia, BAY94-8862); Drug: Type 2 DM drugs

Interventions

Finerenone (Kerendia, BAY94-8862) DRUG

Following the physicians' decision.

Type 2 Diabetes Mellitus patients

Type 2 DM drugs DRUG

Following the physicians' decision

Type 2 Diabetes Mellitus patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

MyTherapy App users in Germany with the Self-reported Type 2 Diabetes Mellitus patients who have been prescribed the drugs defined according inclusion criteria will be eligible to be enrolled.

You may qualify if:

• Patients participating in the Chronic Kidney Disease (CKD) awareness program within myTherapy App
• Patient self-reported diagnosis of Type 2 Diabetes Mellitus
• Patients tracking their adherence for at least one of the following drug containing medical products/devices within myTherapy App: Metformin, Acarbose, Dipeptidyl peptidase (DDP)-4 inhibitors, Glucagon-like peptide (GLP) inhibitors, RAS inhibitors, Sodium-dependent glucose transporters 2 (SGLT2) inhibitors, Basal insulin, Finerenone (once available in Germany), Sulfonylurea, Glucose test strips
• Adult (≥ 18 years) female, male or diverse patient
• Signed informed consent

You may not qualify if:

• Patient self-reported diagnosis of Type 1 Diabetes Mellitus
• Patients tracking their adherence for at least one of the following medical products: Insulin pump

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Many locations

Multiple Locations, Germany

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic

Interventions

finerenone

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2022
• First Posted: September 23, 2022
• Study Start: August 18, 2023
• Primary Completion: November 18, 2025
• Study Completion: November 18, 2025
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)